drugset / Trial / NCT00220051

A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer

NCT00220051 ↗

Phase 2 Completed 109 enrolled Royal Marsden NHS Foundation Trust
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the treatment of patients with locally advanced or inoperable rectal cancer.

Timeline

Start
2001-11
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1250 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 —

Indications